Author 木浦 勝行| 谷本 安| 田端 雅弘| 金廣 有彦| 上岡 博| 谷本 光音| 渡邊 都貴子| 草野 展周| 小出 典男|
Published Date 2005-05-30
Publication Title 岡山医学会雑誌
Volume volume115
Issue issue1
Content Type Journal Article
Author Kiura, Katsuyuki|
Published Date 2013-08-01
Publication Title 岡山医学会雑誌
Volume volume125
Issue issue2
Content Type Journal Article
Author Kiura, Katsuyuki| Tanimoto, Mitsune|
Published Date 2013-04-01
Publication Title 岡山医学会雑誌
Volume volume125
Issue issue1
Content Type Journal Article
Title Alternative Treatment for a non-compliant patient with cancer and epilepsy
FullText URL 126_133.pdf
Author Minami, Daisuke| Ichihara, Eiki| Okabe, Nobuyuki| Yokomichi, Naosuke| Kouge, Noriko| Kajizono, Makoto| Akimoto, Yutaka| Hori, Keisuke| Matsubara, Minoru| Nasu, Junichiro| Tanimoto, Mitsune| Kiura, Katsuyuki| Matsuoka, Junzi|
Abstract  A 58-year-old man with cervical esophageal cancer and a history of epilepsy was treated with chemoradiotherapy from May of 2013. When tube feeding was initiated due to aspiration pneumonitis, the patient showed a degree of irritability that affected routine staff work and treatment compliance. We attempted to perform supportive care for maladjustment by the notice, the fast, and the tube feeding, but there was no improvement. After we added carbamazepine, primidone, and propericiazine (which had been canceled at the initiation of the tube feeding) to the patient's intravenous phenytoin, the symptoms and treatment compliance improved significantly. We concluded that the causes of the patient's irritability were maladjustment and his epilepsy.
Keywords てんかん(epilepsy) 易怒性(irritability) 適応障害(maladjustment)
Publication Title 岡山医学会雑誌
Published Date 2014-08-01
Volume volume126
Issue issue2
Start Page 133
End Page 135
ISSN 0030-1558
language 日本語
Copyright Holders Copyright (c) 2014 岡山医学会
File Version publisher
DOI 10.4044/joma.126.133
NAID 130004685264
Author Ichihara, Eiki| Ohashi, Kadoaki| Takigawa, Nagio| Osawa, Masahiro| Ogino, Atsuko| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2011-04-01
Publication Title 岡山医学会雑誌
Volume volume123
Issue issue1
Content Type Journal Article
Author Taniguchi, Akihiko| Miyahara, Nobuaki| Nakahara, Atsushi| Takata, Saburo| Sakugawa, Ryo| Nagano, Osamu| Tanimoto, Yasushi| Kanehiro, Arihiko| Kiura, Katsuyuki| Ujike, Yoshito| Tanimoto, Mitsune|
Published Date 2011-12-01
Publication Title 岡山医学会雑誌
Volume volume123
Issue issue3
Content Type Journal Article
Author Ichihara, Eiki| Matsuoka, Junji| Takigawa, Nagio| Matsuzaki, Takashi| Katsui, Kuniaki| Kiura, Katsuyuki| Tanimoto, Mitsune|
Published Date 2009-12-01
Publication Title 岡山医学会雑誌
Volume volume121
Issue issue3
Content Type Journal Article
Author 谷本 安| 佐久川 亮| 木浦 勝行| 谷本 光音|
Published Date 2005-01-31
Publication Title 岡山医学会雑誌
Volume volume116
Issue issue3
Content Type Journal Article
JaLCDOI 10.18926/AMO/61429
FullText URL 75_1_15.pdf
Author Katsui, Kuniaki| Ogata, Takeshi| Tada, Akihiro| Sugiyama, Soichi| Yoshio, Kotaro| Kuroda, Masahiro| Kiura, Katsuyuki| Maeda, Yoshinobu| Toyooka, Shinichi| Hiraki, Takao| Kanazawa, Susumu|
Abstract The aim of this study was to investigate whether volumetric positron emission tomography (PET) parameters are prognostic predictors in stage III non-small cell lung cancer patients receiving definitive concurrent chemo-radiotherapy (CCRT) with cisplatin/docetaxel. Cases involving definitive CCRT were reviewed retrospectively, and the maximum standardized uptake value, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated. The relationships between these PET parameters and prognosis were analyzed. MTV and TLG were significant predictors of distant metastasis-free survival (DMFS) (p = 0.0003 and 0.0005, respectively) and progression-free survival (PFS) (p = 0.001 and 0.0007, respectively). The three-year DMFS rates in patients with low and high MTV were 13.3% and 64.6%, respectively, and the corresponding values in those with low and high TLG were 13.3% and 65.2%, respectively. The three-year PFS rates in patients with low and high MTV were 13.3% and 57.8%, respectively, and the corresponding values in patients with low and high TLG were 13.3% and 57.8%, respectively. However, MTV and TLG were not predictors of local control or overall sur-vival. We demonstrated that volumetric PET parameters were predictors of patients receiving definitive CCRT. Our findings contradict the findings of previous reports and warrant further research to validate them.
Keywords volumetric positron emission tomography parameters distant metastasis-free survival chemoradiotherapy cisplatin/docetaxel non-small cell lung cancer
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2021-02
Volume volume75
Issue issue1
Publisher Okayama University Medical School
Start Page 15
End Page 23
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2021 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 33649609
Author Takeda, Hiromasa| Takigawa, Nagio| Ohashi, Kadoaki| Minami, Daisuke| Kataoka, Itaru| Ichihara, Eiki| Ochi, Nobuaki| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2013-02-15
Publication Title Experimental Cell Research
Volume volume319
Issue issue4
Content Type Journal Article
FullText URL fulltext.pdf
Author Watanabe, Hiromi| Ichihara, Eiki| Kayatani, Hiroe| Makimoto, Go| Ninomiya, Kiichiro| Nishii, Kazuya| Higo, Hisao| Ando, Chihiro| Okawa, Sachi| Nakasuka, Takamasa| Kano, Hirohisa| Hara, Naofumi| Hirabae, Atsuko| Kato, Yuka| Ninomiya, Takashi| Kubo, Toshio| Rai, Kammei| Ohashi, Kadoaki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki|
Published Date 2021-01-07
Publication Title Cancer science
Publisher Wiley
ISSN 1347-9032
NCID AA11808050
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2021 The Authors.
File Version publisher
PubMed ID 33410241
NAID 120007008532
DOI 10.1111/cas.14801
Web of Science KeyUT 000630136900001
Related Url isVersionOf https://doi.org/10.1111/cas.14801
FullText URL fulltext.pdf
Author Kano, Hirohisa| Ichihara, Eiki| Harada, Daijiro| Inoue, Koji| Kayatani, Hiroe| Hosokawa, Shinobu| Kishino, Daizo| Watanabe, Kazuhiko| Ochi, Nobuaki| Oda, Naohiro| Hara, Naofumi| Ninomiya, Kiichiro| Hotta, Katsuyuki| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords immune checkpoint inhibitor non-small cell-lung cancer PD-L1 pembrolizumab poor performance status
Published Date 2020-07-29
Publication Title Cancer Science
Volume volume111
Issue issue10
Publisher Wiley
Start Page 3739
End Page 3746
ISSN 1347-9032
NCID AA11808050
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 The Authors.
File Version publisher
PubMed ID 32726470
DOI 10.1111/cas.14590
Web of Science KeyUT 000562490200001
Related Url isVersionOf https://doi.org/10.1111/cas.14590
JaLCDOI 10.18926/AMO/32866
FullText URL fulltext.pdf
Author Fujimoto, Nobukazu| Kiura, Katsuyuki| Takigawa, Nagio| Fujiwara, Yoshiro| Toyooka, Shinichi| Umemura, Shigeki| Tabata, Masahiro| Ueoka, Hiroshi| Tanimoto, Mitsune|
Abstract <p>We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively. Twenty-five patients (21 men and 4 women) with NSCLC and good performance status who were &#60;70 years old were analyzed. The median age was 58 years. Most patients had performance status 1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25). Cisplatin and docetaxel were given on day 1 and irinotecan on day 2;the cycle was repeated every 3 weeks. The objective response rate was 39.1% (95% confidence interval:18.7-59.5%). The median survival time and actual 2-, 3-, and 5-year survival rates were 14.3 months, 32%, 20%, and 8%, respectively. Of note, only 6 patients were treated with gefitinib at the recurrence after triplet chemotherapy;of these, 4 (67%) achieved a partial response, which might result in favorable survival. Grade 3/4 toxicities consisted of neutropenia (100%), neutropenic fever (56%), nausea/vomiting (40%), and diarrhea (16%);no cases of treatment-related death occurred. Triplet chemotherapy showed impressive survival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the clinical practice.</p>
Keywords cisplatin docetaxel irinotecan triplet chemotherapy gefitinib
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2010-02
Volume volume64
Issue issue1
Publisher Okayama University Medical School
Start Page 33
End Page 37
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 20200582
Web of Science KeyUT 000274868300005
FullText URL fulltext20210810-3.pdf
Author Nishii, Kazuya| Ohashi, Kadoaki| Watanabe, Hiromi| Makimoto, Go| Nakasuka, Takamasa| Higo, Hisao| Ninomiya, Kiichiro| Kato, Yuka| Kubo, Toshio| Rai, Kammei| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords epidermal growth factor receptor osimertinib bevacizumab cetuximab hypoxia‑inducible factor‑1α transforming growth factor‑α
Published Date 2021-7-7
Publication Title Oncology Letters
Volume volume22
Issue issue3
Publisher Spandidos Publications
Start Page 639
ISSN 1792-1074
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © Nishii et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
File Version publisher
DOI 10.3892/ol.2021.12900
Web of Science KeyUT 000678494600001
Related Url isVersionOf https://doi.org/10.3892/ol.2021.12900
FullText URL fulltext.pdf
Author Kitamura, Wataru| Asada, Noboru| Tabata, Tetsuya| Shibata, Rei| Nishi, Tatsuya| Kato, Yuka| Takasuka, Hiroki| Fujiwara, Hideaki| Ennishi, Daisuke| Nishimori, Hisakazu| Fujii, Nobuharu| Matsuoka, Ken-Ichi| Kiura, Katsuyuki| Yoshino, Tadashi| Maeda, Yoshinobu|
Keywords marginal zone lymphoma diffuse large B-cell lymphoma anterior mediastinum cystic lesions
Published Date 2022
Publication Title Journal Of Clinical And Experimental Hematopatholo
Volume volume62
Issue issue1
Publisher The Japanese Society for Lymphoreticular Tissue Research
Start Page 35
End Page 40
ISSN 1346-4280
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2021 The Japanese Society for Lymphoreticular Tissue Research
File Version publisher
PubMed ID 34840205
DOI 10.3960/jslrt.21010
Web of Science KeyUT 000766876600003
Related Url isVersionOf https://doi.org/10.3960/jslrt.21010
JaLCDOI 10.18926/AMO/47260
FullText URL 65_6_353.pdf
Author Ichihara, Eiki| Kiura, Katsuyuki| Tanimoto, Mitsune|
Abstract Angiogenesis is an essential process in tumor growth. The concept of angiogenesis, when proposed by Folksman in 1971, had a great impact on cancer research and therapy, as the survival and proliferation of cancer depend on angiogenesis, which could be a target of cancer therapy. In subsequent decades, numerous antiangiogenic agents were developed, and some of them have been applied clinically. However, angiogenesis includes a complex and multistep process that has not been sufficiently elucidated. In this review, we focus on signaling pathways related with tumor angiogenesis and several antiangiogenic agents approved by the United States Food and Drug Administration or under investigation.
Keywords angiogenesis cancer
Amo Type Review
Publication Title Acta Medica Okayama
Published Date 2011-12
Volume volume65
Issue issue6
Publisher Okayama University Medical School
Start Page 353
End Page 362
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2011 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 22189475
Web of Science KeyUT 000298516900001
FullText URL fulltext.pdf figs.pdf tables.pdf
Author Itano, Junko| Higo, Hisao| Ohashi, Kadoaki| Makimoto, Go| Nishii, Kazuya| Hotta, Katsuyuki| Miyahara, Nobuaki| Maeda, Yoshinobu| Kiura, Katsuyuki|
Keywords osimertinib drug-induced ILD reversed halo sign organizing pneumonia pattern re-administration
Published Date 2020-03-15
Publication Title Internal Medicine
Volume volume59
Issue issue6
Publisher The Japanese Society of Internal Medicine
Start Page 823
End Page 828
ISSN 0918-2918
NCID AA10827774
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2020 by The Japanese Society of Internal Medicine
File Version author
PubMed ID 31787696
DOI 10.2169/internalmedicine.3689-19
Web of Science KeyUT 000521137500011
Related Url isVersionOf https://doi.org/10.2169/internalmedicine.3689-19
Author Kubo, Toshio| Takigawa, Nagio| Osawa, Masahiro| Harada, Daijiro| Ninomiya, Takashi| Ochi, Nobuaki| Ichihara, Eiki| Yamane, Hiromichi| Tanimoto, Mitsune| Kiura, Katsuyuki|
Published Date 2013-01
Publication Title Cancer Science
Volume volume104
Issue issue1
Content Type Journal Article
JaLCDOI 10.18926/AMO/54514
FullText URL 70_4_327.pdf
Author Watanabe, Mototsugu| Yamamoto, Hiromasa| Eikawa, Shingo| Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Hotta, Katsuyuki| Wada, Jun| Hinotsu, Shiro| Fujiwara, Toshiyoshi| Kiura, Katsuyuki| Doihara, Hiroyoshi| Miyoshi, Shinichiro| Udono, Heiichiro| Toyooka, Shinichi|
Abstract A study to evaluate the effect of metformin on the immune system was commenced in July 2014. Metformin is one of the most commonly prescribed drugs for type 2 diabetes, and previous studies have reported that metformin has an anti-tumor effect. The aim of this study is to evaluate the efficacy of metformin on the immune system in human cancer patients in vivo. The primary outcome parameter will be the rate change in the population of CD8+ T cells, which produce multiple cytokines.
Keywords metformin CD8+ T cells cancer immunology
Amo Type Clinical Study Protocols
Publication Title Acta Medica Okayama
Published Date 2016-08
Volume volume70
Issue issue4
Publisher Okayama University Medical School
Start Page 327
End Page 330
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 27549683
Web of Science KeyUT 000384748600018
Author Ueno, Tsuyoshi| Tsukuda, Kazunori| Toyooka, Shinichi| Ando, Midori| Takaoka, Munenori| Soh, Junichi| Asano, Hiroaki| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Shien, Kazuhiko| Furukawa, Masashi| Yamatsuji, Tomoki| Kiura, Katsuyuki| Naomoto, Yoshio| Miyoshi, Shinichiro|
Published Date 2012-04
Publication Title Lung Cancer
Volume volume76
Issue issue1
Content Type Journal Article